Cardiol Therapeutics INC 20-F annual reports
The annual report filed by foreign private issuers listed on a US exchange — the 10-K’s equivalent for non-US companies.
NASDAQ
Cardiol Therapeutics secures an exclusive worldwide license from Meros Polymers for their cannabinoid delivery technology, aiming to develop novel therapies for cardiovascular and cardiopulmonary diseases.